No attachments available.
Cancer Trials Support Unit
The National Institutes of Health, National Cancer Institute, awarded an Indefinite Delivery, Indefinite Quantity (IDIQ) contract to support the Cancer Trials Support Unit (CTSU). This award, identified by contract number 75N91022D00013 and solicitation number 75N91021R00021, carries a maximum potential value of $548,000,000 if all options are exercised. The scope of the work specifically includes Task Area 1 for project kick-off and transition activities, as well as Task Area 3 for awareness, education, and training.
The primary classification for this requirement falls under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and PSC AN13, Health R&D Services; Health Care Services; Experimental Development. The procurement was conducted under a small business program set-aside, designated by the SBP acronym and explanation. Performance will take place within the United States, with the award finalized and published on July 28, 2022.
Chris Shih serves as the point of contact for this award notice, which was issued by the NIH NCI office. The contract provides a framework for ongoing services related to the CTSU program, and no additional attachments were included with the formal award notification.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.
Contact and place of performance
Chris Shih
USA
Contract Title: Cancer Trials Support Unit (CTSU) The IDIQ contract number 75N91022D00013 was awarded against solicitation number 75N91021R00021. The maximum value of the IDIQ contract is $548,000,000 if all options are exercised. Task Areas Awarded: Task Area 1: Project Kick-off Meeting/Transition Activities Task Area 3: Awareness, Education, and Training (AET)